The Annals Evolution of Clinical Pharmacy | Now Available
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     



Published Online, 28 April 2009, www.theannals.com, DOI 10.1345/aph.1L656.
The Annals of Pharmacotherapy: Vol. 43, No. 5, pp. 944-949. DOI 10.1345/aph.1L656
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fan, L.
Right arrow Articles by Zhou, H.-H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fan, L.
Right arrow Articles by Zhou, H.-H.

Effects of Ginkgo biloba Extract Ingestion on the Pharmacokinetics of Talinolol in Healthy Chinese Volunteers

Lan Fan, PhD

Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University, Changsha, Hunan, China

Gong-You Tao, MD

Pharmacology student, Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Guo Wang, PhD

Postdoctoral student, Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Yao Chen, PhD

Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Wei Zhang, PhD

Vice Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Yi-Jing He, PhD

Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Qing Li, PhD

Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

He-Ping Lei, PhD

Pharmacology student, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Feng Jiang, PhD

Assistant Professor, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Dong-Li Hu, MD

Pharmacology student, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Yuan-Fei Huang, MD

Pharmacology student, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Hong-Hao Zhou, MD

Professor, Director, Pharmacogenetics Research Institute, Institute of Clinical Pharmacology, Central South University

Reprints: Dr. Hong-Hao Zhou, Pharmacogenetics Research Institute, Central South University, 110 Xiang Ya Rd., Changsha, Hunan 410078, China, fax 86 731 2354476, hhzhou2003{at}163.com

BACKGROUND: Ginkgo biloba extract (GBE), the best selling herbal medicine in the world, has been reported to inhibit P-glycoprotein in vitro. However, the effects of GBE on P-glycoprotein activity in humans have not been clarified.

OBJECTIVE: To investigate the effects of single and repeated GBE ingestion on the oral pharmacokinetics of talinolol, a substrate drug for P-glycoprotein in humans.

METHODS: Ten unrelated healthy male volunteers were selected to participate in a 3-stage sequential study. Plasma concentrations of talinolol from 0 to 24 hours were measured by high-performance liquid chromatography after talinolol 100 mg was administrated alone, with a single oral dose of GBE (120 mg), and after 14 days of repeated GBE ingestion (360 mg/day).

RESULTS: A single oral dose of GBE did not affect the pharmacokinetics of talinolol. Repeated ingestion of GBE increased the talinolol maximum plasma concentration (Cmax) by 36% (90% CI 10 to 68; p = 0.025), the area under the concentration-time curve (AUC)0-24 by 26% (90% CI 11 to 43; p = 0.008) and AUC0-{infty} by 22% (90% CI 8 to 37; p = 0.014), respectively, without significant changes in elimination half-life and the time to Cmax.

CONCLUSIONS: Our results suggest that long-term use of GBE significantly influenced talinolol disposition in humans, likely by affecting the activity of P-glycoprotein and/or other drug transporters.

Key Words: Gingko biloba extract, herb-drug interaction, P-glycoprotein inhibition, pharmacokinetics, talinolol

Published Online, April 28, 2009. www.theannals.com, DOI 10.1345/aph.1L656





homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.